Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Organisation › Details

Minoryx Therapeutics S.L.

Minoryx is a clinical stage biotech company piloting the development of new therapies for X-ALD and other rare diseases of genetic origin with a high unmet medical need. The company’s lead program is MIN-102, which may be effective in multiple CNS indications beyond X-ALD. The Minoryx team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors, has support from a network of other organizations and has operations in Spain and Belgium. Minoryx was founded in 2011 and has raised a total of €50M. *


Period Start 2011-01-01 established
  Group Minoryx (Group)
Products Industry DRUGS, ORPHAN
  Industry 2 MIN-102 (Minoryx)
Person Person Martinell, Marc (Minoryx Therapeutics SL 201404 CEO + Co-Founder)
Region Region Barcelona
  Country Spain (Espańa)
  Street 32 Av. Ernest Lluch
TecnoCampus MAtaró-Maresme, TCM2
  City 08302 Mataró (Barcelona)
  Tel +34-93-702-1975
    Address record changed: 2018-07-24
Basic data Employees n. a.
    * Document for ďż˝About Sectionďż˝: Minoryx Therapeutics S.L.. (1/15/19). "Press Release: Minoryx Therapeutics Extends Its Activities in Belgium". Mataró, Barcelona & Charleroi.
Record changed: 2019-05-30


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Minoryx (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top